VERV Investors Get Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Litigation with Schall Law Firm

Schall Law Firm, a national litigation firm focused on shareholder rights litigation, reminds investors of a class action lawsuit against Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV) for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 9, 2022 and April 1, 2024, inclusive (the “Class Period”), are encouraged to contact the Firm before October 28, 2024.